---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-047406"
form_type: "8-K"
ticker: "XFOR"
cik: "0001501697"
company_name: "X4 Pharmaceuticals, Inc"
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T00:53:16.849040+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# X4 Pharma Q3 net loss $36.7M; positive Phase 2 CN data; XOLREMDI launch underway

## Summary
- Q3 net loss $36.7M vs $2.3M loss in Q3 2023; includes $1.9M non-cash loss on warrant liability.
- Net product revenue of $0.6M from XOLREMDI (mavorixafor) for WHIM syndrome, launched April 2024.
- Positive Phase 2 results: mavorixafor durably increased absolute neutrophil counts and enabled G-CSF reduction in chronic neutropenia.
- Phase 3 4WARD trial on track to fully enroll mid-2025; regulatory approvals in ~85% of targeted countries.
- Cash $135.8M, sufficient into late 2025 (excludes potential XOLREMDI revenue).

## SEC filing metadata
- accession: 0001628280-24-047406
- form_type: 8-K
- ticker: XFOR
- cik: 0001501697
- company_name: X4 Pharmaceuticals, Inc
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501697/000162828024047406/0001628280-24-047406-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501697/000162828024047406/xfor-20241113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-047406
- JSON: https://secwatch.observer/filing/0001628280-24-047406.json
- Plain text: https://secwatch.observer/filing/0001628280-24-047406.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.